NUMBERS UP FOR ASPRIN
Share this on

NUMBERS UP FOR ASPRIN

Dr Robyn Woods remembers feeling a moment of panic in 2008 when she received the excited phone call from her Monash University colleague, Professor John McNeil, telling her the clinical study that he led and she managed had received US$50 million (A$48 million) from the US National Institutes of Health (NIH). The phone call marked a major escalation of the ‘ASPirin In Reducing Events in the Elderly’ trial (ASPREE ), from a pilot study of 200 participants in Melbourne, Australia, to an international exercise jointly run with researchers in the US, where it would be one of the largest clinical trials in older persons ever funded by the US National Institute on Aging, part of the NIH. ASPREE aims to answer the question of whether people over 70 who take daily low dose aspirin will lead healthier lives for longer. Professor McNeil, head of the School of Public Health and Preventive Medicine at Monash and an epidemiologist, realised early in the planning of the study that the question could only be answered with a large, well-controlled clinical trial. The Monash University team joined forces with the Berman Center for Outcomes and Clinical Research in the US, along with Australian collaborators including the University of Tasmania, the Australian National University and the University of Melbourne

This article:
/>

NUMBERS UP FOR ASPRIN